Prior Authorization Required

Prior authorization is required for covered IORT CPT codes and for IORT procedures where the member's benefit plan requires authorization. Requests should document that the patient meets the policy's medical necessity criteria and reference the specific covered CPT/ICD-10 codes. Providers must obtain prior authorization where required by the benefit plan; failure to do so may affect coverage.

• Affected CPT codes include 77424 (IORT x-ray), 77425 (IORT electrons), and 77469 (IORT management) when selection criteria are met.
• Include plan-specific authorization number and verify benefit plan prior-auth requirements before scheduling.

Prior Authorization — Clinical and Technical Details

Prior authorization requests for IORT should include the clinical indication, planned IORT technique and single-fraction dose, and whether supplemental external-beam radiation therapy (EBRT) is planned. For breast cancer, document whether a risk-adapted plan is intended (e.g., TARGIT approach with EBRT reserved for defined adverse pathology).

• Essential items: diagnosis and stage, tumor size, nodal status, surgical margin status, histology, planned IORT device/energy (electrons vs low-energy x-ray vs brachytherapy), single-fraction dose and prescription depth/volume.
• Planned EBRT fields, dose/fractionation (if any), and criteria that would trigger supplemental EBRT (pathology triggers).

Prior Authorization — Risk-Adapted Breast IORT

For breast-conserving surgery IORT performed within a risk-adapted strategy, prior authorization should capture the risk-adapted nature of the plan and note that supplemental EBRT was used in a subset of trial patients. Authorization should confirm eligibility consistent with the policy's selection criteria or trial-derived 'suitable' definitions.

• Document whether the approach follows a trial-based risk-adapted protocol (e.g., TARGIT-A) and the anticipated percentage of patients expected to receive supplemental EBRT.
• Note that supplemental EBRT was required in approximately 14–15% of patients in trials when adverse pathology was found.

Pancreatic IORT — Specialized-Center Prior Authorization

Pancreatic IORT is controversial and, per NCCN guidance, should be limited to specialized centers. Prior authorization for pancreatic IORT must indicate specialized-center capability and experience; deviations from specialized-center expectation may be denied.

• Provide documentation of specialized-center designation, multidisciplinary tumor board review, surgeon/radiation oncologist IORT experience, and protocol under which IORT will be delivered.
• Include literature justification or clinical trial enrollment if applicable; absence of specialized-center criteria may result in non-authorization.

Prior Authorization — Patient Selection

Patient selection and prior authorization notes: electron-beam IORT for partial-breast treatment should be restricted to women meeting 'suitable' APBI selection criteria. Low-energy x-ray IORT should be used within a clinical trial or registry per ASTRO CED statements; authorization should reflect these conditions.

• For breast IORT, document age, tumor size, histology (non-lobular preferred), nodal status (pN0/pNmic), receptor status, grade, and Ki-67 when available.
• When IORT is being requested outside of recommended selection criteria or outside a registry/trial, include rationale and supportive evidence; such cases carry higher denial risk.

Denial Risk — Investigational Indications

Denial risk exists for investigational indications listed in the policy. IORT is considered experimental/investigational for multiple disease sites; requests for these indications should be expected to be denied unless compelling evidence or trial context is provided.

• Common investigational indications include brain tumors (primary glioblastoma), cholangiocarcinoma, gastric cancer, pancreatic cancer (outside specialized centers), prostate cancer, spinal metastases, thymoma, and others listed in the policy.
• Provide clinical trial enrollment information or prospective registry documentation if proposing IORT for investigational indications.

Denial Risk — Complication and Outcome Concerns

Complication- and outcome-related denial risk: evidence of increased surgical morbidity or lack of survival benefit in some indications may justify denial or the need for additional documentation. Prior authorization should address perioperative risk and expected benefit.

• Examples: higher surgical complications reported with IORT in some gastric cancer series; provide justification if used for such indications.
• Include anticipated perioperative morbidity mitigation plans and multidisciplinary assessment.

Denial Risk — Clinical Exclusions and Contraindications

Clinical exclusion-related denial risks should be documented and considered before authorization. Contraindications or exclusion criteria in the policy (e.g., prior radiation to the same breast/chest, contraindications to radiation, extensive intraductal component, tumor in axillary tail) may disqualify a patient from coverage.

• Document prior radiation history to the same site, presence of extensive intraductal component, tumor location (axillary tail), and any absolute contraindications to radiation.
• If any exclusion applies, prior authorization should be denied or require clear rationale for exception.

Counseling and Registry Expectations

Providers should counsel patients on expected comparative risks and consider enrollment in registries for certain IORT modalities. For breast cancer, counsel that trials showed higher ipsilateral breast tumor recurrence (IBTR) with some IORT approaches versus whole-breast irradiation, and document that counseling in the authorization record.

• Document shared decision-making that includes discussion of increased IBTR risk and alternative options such as hypofractionated whole-breast RT.
• When low-energy x-ray IORT is used, document registry enrollment or trial participation per ASTRO CED guidance.

Documentation to Support Coverage

Documentation to support coverage must include clinical and procedural records consistent with covered CPT and ICD-10 codes and the medical necessity criteria in the policy. Prior authorization records should be retained and made available upon request.

• Include operative note, pathology report, final margin status, staging, imaging, and radiation oncology treatment plan.
• Include the CPT/ICD-10 codes being billed and cross-reference to the policy's covered code list.

Essential Clinical Documentation

Essential clinical documentation required for authorization: tumor stage, nodal status, margins, single-fraction dose, device/energy used, prior radiation history, and any planned or prior EBRT. Include criteria that would trigger supplemental EBRT and multidisciplinary review notes.

• Tumor size and stage (T/N), histology, margin distance, and presence/absence of extensive intraductal component.
• Planned IORT dose (e.g., 21 Gy electrons, 20 Gy low-energy x-ray, or Cs-131 brachytherapy prescription) and prescription depth/volume.

Required Clinical and Procedural Documentation

Required clinical documentation at the time of procedure and for post-procedure review: informed consent specific to IORT, operative details, resection margin measurement (example: 1 cm when applicable), intraoperative decisions, frozen-section pathology when used, and delivered dose/seed counts for brachytherapy.

• Informed consent describing risks/benefits and alternatives including WBI or hypofractionated EBRT.
• For brachytherapy (brain implants), include cavity size/volume, number of seeds, seed activity, and dosimetry summary.

Intraoperative Decision and Targeting Documentation

Intraoperative decision-making and targeting documentation should capture the rationale for delivering IORT, any change in plan based on frozen-section pathology or intraoperative findings, and exact targeting/positioning information.

• Record intraoperative findings that altered the plan (e.g., positive margin, unexpected nodal disease) and resulting actions (e.g., decision to abort IORT or to plan supplemental EBRT).
• Include shielding or mobilization techniques used to protect organs at risk.

IORT Procedural and Dosimetric Documentation (Brain/Brachytherapy)

IORT procedural and dosimetric documentation for brain implants (e.g., Cs-131) must include histology, cavity dimensions/volume, number of seeds used, activity per seed and total activity, and delivered dose with prescription depth. These technical details are required for authorization and post-procedure review.

• Provide seed model, number, activity (mCi) per seed, total activity, cavity volume (cm3), and prescription dose (e.g., 80 Gy at 5 mm).
• Include immediate postoperative imaging if used to confirm implant positioning.

Policy Documentation and Provider Responsibility

Policy documentation and administrative responsibilities: include the policy history and review dates in authorization records when applicable. Clinical Policy Bulletins are intended to assist in administering plan benefits; participating providers remain responsible for medical advice and treatment decisions.

• Reference policy number 0721 and effective date 2006-03-17 in authorization documentation when relevant.
• Providers remain responsible for patient care; CPBs do not guarantee coverage and are not medical advice.

Step Therapy / Sequencing Considerations

Step therapy and sequencing notes: there is no mandated step therapy for IORT in this policy. Consider whole-breast hypofractionated EBRT as an established alternative when treatment duration or long-term data for IORT are concerns. IORT is often part of multidisciplinary care and can be used as a boost in selected cases.

• When requestors cite convenience as primary rationale, document consideration of hypofractionated WBRT schedules as a viable alternative.
• No formal step-through therapies are required by this policy; document the clinical reasoning for selecting IORT over alternatives.

Potential Denial Rationale and Evidence Expectations

Potential denial rationale: limited evidence for certain devices/indications (for example, INTRABEAM for invasive thymoma or pancreatic uses outside specialized centers) may justify denial or requirement for additional documentation or registry/trial enrollment.

• Requests for uncommon indications should include high-quality evidence or clinical trial/registry participation to avoid denial.
• Administrative denials may follow when documentation does not meet policy criteria or when benefit plan provisions are not followed.